|
Viktor Roschke, Ph.D. joined CoGenesys at its inception. At CoGenesys, Dr. Roschke oversees development and characterization of lead product candidates to support both internal pipeline and outlicensing opportunities. Prior to joining CoGenesys, Dr. Roschke held the position of Director, Clinical Immunology at Human Genome Sciences, where he was responsible for directing the development and implementation of GLP-compliant assays in support of all HGS pre-clinical and clinical programs. Prior to this, Dr. Roschke was Associate Director in the Antibody Development Department responsible for identification and characterization of new therapeutic antibody candidates. Dr. Roschke joined Human Genome Sciences as a Scientist in 1997 from National Cancer Institute, where he studied the mechanisms of development of B-cell malignancies. Prior to his move to United States in 1992, Dr. Roschke held several positions at the Novosibirsk Institute of Bioorganic Chemistry of the Russian Academy of Sciences, including Head of Laboratory of Immunochemistry and Scientific Director of an affiliated biotech company BioSAN. Dr. Roschke received his Ph.D. in Molecular Biology from Novosibirsk Institute of Bioorganic Chemistry and his MS in Biochemistry from Novosibirsk University, Russia. He has published over 40 papers in peer-reviewed journals and has 13 issued patents. | 